Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Enzalutamide monotherapy in patients with hormone-naïve prostate cancer: 1.year extended follow-up of a phase 2 study.

Research output: Contribution to journalConference abstract in journalResearch

  1. ERG-expression is an independent predictor of disease progression during active surveillance

    Research output: Contribution to journalConference abstract in journalResearch

  2. Baseline PSA level in prediction of prostate cancer risk and aggressiveness: A Danish population-based cohort study.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Is PSA doubling time reliable as a progression risk criterion for patients with low-risk prostate cancer in an active surveillance programme?

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • Michael Borre
  • Matthew Smith
  • Per Rathenborg
  • Patrick Werbrouck
  • Hendrik van Poppel
  • Axel Heidenreich
  • Peter Iversen
  • Johan Braeckman
  • Jiri Heracek
  • Edwina Baskin-Bey
  • Taoufik Ouatas
  • Frank Perabo
  • D. Phung
  • Benoit Baron
  • Mohammad Hirmand
  • Bertrand Tombal
View graph of relations
Original languageEnglish
Article numberP060
JournalEuropean Urology Supplements
Volume13
Issue number131
Pages (from-to)131
ISSN1569-9056
Publication statusPublished - 2014

ID: 44979120